ABOUT HUGEL
New Hope, Better Life
History
GLOBALIZATION
-
2020
- 10
- Received approval from China NMPA for botulinum toxin product, Letybo
Broke ground for toxin no. 3 capacity
- 09
- Acquired 80% stake of J World, PDO thread manufacturer
- 06
- Merged with AB Bio Inc
Submitted BLA for botulinum toxin in EU
- 04
- Broke ground for new filler capacity
-
2019
- 12
- ‘WELLAGE’ obtained NMPA approval in China
(4 basic skincare products, 3 sheet masks)
Increased stake in Across to 83.83%
- 11
- Obtained additional indication approval for
botulinum toxin(crow’s feet)
- 07
- Merged with Dongyang HC
- 04
- Filed NDA for botulinum toxin in China
- 01
- Received marketing approval for botulinum toxin in Taiwan
Completed phase III clinical trial(Bless 1,2) for
botulinum toxin in US/Poland/Germany
-
2018
- 10
- Established US subsidiary, Hugel America Inc
- 09
- Launched premium HA filler ‘The Chaeum Style’
- 07
- Completed phase III clinical trial for botulinum toxin in China
- 01
- Merged with Hugel Pharma and Hugel Meditec
Official launch of ‘WELLAGE One Day Kit’ product
-
2017
- 12
- Increased stake in Across to 65.06%
- 10
- Obtained marketing approval for penile enhancement filler,
‘The Chaeum SHAPE 10’
- 07
- Change in major shareholder to Leguh Issuer Designated Activity Company
- 02
- Obtained marketing approval for botulinum toxin in Brazil
-
2016
- 11
- Obtained marketing approval for botulinum toxin in Russia
- 06
- Obtained additional indication approval for
botulinum toxin(foot deformity in pediatric cerebral palsy)
- 05
- Received IND approval for phase III clinical trial for
botulinum toxin in China
- 04
- Obtained additional indication approval for
botulinum toxin(post-stroke upper-limb spasticity)
- 03
- Received IND approval for phase III clinical trial for
botulinum toxin in Germany and Poland